Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993236priorityCriticalpatent/ECSP993236A/en
Publication of ECSP993236ApublicationCriticalpatent/ECSP993236A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Cefuroxima-axetil en un forma no gelatinosa al contacto con un líquido acuoso, por ejemplo en la forma de una solución sólida en un polímero, ó en la forma de una dispersión sólida en un vehículo, por ejemplo útil para la producción de composiciones farmacéuticas que comprenden cefuroxima-axetil como un ingredinete activo, y el uso de cefuroxima-axetil en la fabricación de una forma de dosificación oral que no exhibe un efecto de alimento adverso.Cefuroxime-axetil in a non-gelatinous form on contact with an aqueous liquid, for example in the form of a solid solution in a polymer, or in the form of a solid dispersion in a vehicle, for example useful for the production of pharmaceutical compositions which They comprise cefuroxime-axetil as an active ingredient, and the use of cefuroxime-axetil in the manufacture of an oral dosage form that exhibits no adverse food effect.
ECSP9932361999-11-251999-11-25
COMPOSITIONS OF ß- LACTAMA
ECSP993236A
(en)
Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
PHARMACEUTICAL FORM WITH INDEPENDENT SUSTAINED RELEASE OF THE PH OF AN ACTIVE INGREDIENT, FOR ACTIVE INGREDIENTS THAT HAVE A SOLUBILITY THAT DEPENDS IN A GREAT MEASURE OF THE PH